|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The leukapheresis market is expected to register a CAGR of nearly 7.5% during the forecast period.
The COVID-19 pandemic positively impacted the market as leukapheresis is a laboratory procedure in which white blood cells, including leukemia cells, are separated from the blood. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2, the virus that causes COVID-19. In May 2020, the National Institutes of Health Clinical Center (CC) (National Institute of Allergy and Infectious Diseases (NIAID) initiated a clinical study to identify how SARS-CoV-2 affects lymphocytes, the immune, and the blood clotting system using the leukapheresis technique by collecting white blood cells from the patients who recovered from COVID-19. Currently, the study is enrolling participants and being conducted at MedStar Georgetown University Hospital and the National Institutes of Health Clinical Center. Also, in April 2020, the combination of Terumo Blood and Cell Technologies’ centrifugal apheresis system and the adsorption cartridge of partner company Marker Therapeutics (Switzerland) received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for treating COVID-19. Thus, considering the significant use of leukapheresis in COVID-19, the market is expected to have steady growth during the forecast period.
The rising incidence of leukemia disorders is expected to boost the demand by increasing the usage rates of leukapheresis machines and kits. Incidence of leukemia is the highest among white people and the lowest among Chinese, Japanese, and Koreans in both men and women. It is the highest among men than women. Some of the signs and symptoms of leukemia are fatigue and weakness, bleeding from gums, trauma, bruising, fever, and weight loss.
According to the Leukemia and Lymphoma Society (2020), every 3 minutes, one person in the United States is diagnosed with blood cancer. According to the North American Association of Central Cancer Registries (NAACCR), in 2022, the country is estimated to record 6,660 cases of acute lymphocytic leukemia. According to the American Cancer Society, 60,530 were diagnosed with leukemia in 2020. In addition, according to Cancer Australia (August 2020), by the end of 2020, 4,527 new cases of leukemia were diagnosed in Australia, including 2,734 men and 1,793 women, compared to 1,958 total diagnosed cases in 2019. Hence, the rising burden of leukemia is creating the need for advanced therapeutics based on leukapheresis for treatment, which is expected to drive the market’s growth over the forecast period.
However, the high cost of therapeutic leukapheresis and stringent regulatory issues for donor recruitment are expected to hinder the growth of the market during the forecast period.
Scope of the Report
Leukapheresis is a laboratory procedure where white blood cells, including leukemia cells, are separated from the blood. The market is segmented by type, application, and geography. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD million for the above segments.
Key Market Trends
Apheresis Device Segment is Expected to Hold a Significant Share in the Leukapheresis Market
Apheresis devices are used to collect and separate blood components for therapeutic and donation procedures. The devices are inbuilt with some safety units, such as an optical fluid level detector, ultrasonic air-bubble detectors, dry heat fluid warmers, and pressure sensors.
COVID-19 is likely to have a profound impact on the segment studied. This technique is now widely used to treat COVID-19 as a plasma therapy. For instance, medical equipment that carries out the apheresis procedure was installed at the Government Medical College Hospital t near Thrissur, Kerala (India), in May 2020, and the technique was used for the first time in India to administer plasma to a 51-year-old man who was suffering from COVID-19.
Furthermore, many companies are focusing on launching new products, contributing to the market’s growth. As per a May 2020 news article, researchers at the University of Houston (UH) are developing a new device to treat babies with blood disorders by adapting microfluidic technology. This technology can help leukapheresis to increase access to cell-based therapies, which may increase its demand in the future.
For instance, in August 2020, the Drugs Controller General of India (DGCI) approved the use of an apheresis machine to extract blood plasma in Goa for critically ill COVID-19 patients. In April 2020, Terumo BCT Inc. and Marker Therapeutics AG received the US FDA approval for the Emergency Use Authorization (EUA) of Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat COVID-19 patients aged 18 years or above.
The expansion of key market players is another reason for the market’s growth. For instance, in January 2020, Fresenius Kabi expanded the transfusion and apheresis disposables plant in the Dominican Republic. Hence, due to such factors, along with rising technological advancements, the apheresis device segment is expected to witness growth during the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is expected to hold a large market share in the leukapheresis market due to the rising geriatric population and increasing prevalence and incidence of leukemia in the region. According to the North American Association of Central Cancer Registries (NAACCR), in 2022, approximately 60,650 people are expected to be diagnosed with leukemia.
According to the Terry Fox Research Institute, an estimated 21,700 people were diagnosed with blood cancers in Canada in 2019. These cancers affect people of all ages, and survival rates are highly dependent on the type of blood cancer. It is estimated that 7,500 Canadians die from blood cancers, making them the third leading cause of cancer-related deaths in the country.
Moreover, market players are frequently launching novel products. For instance, in October 2020, Discovery Life Sciences, a US-based company, launched its GMP-compliant Discovery Leukopaks and other cell-based products for use in the human cell and gene therapy research, development, and manufacturing programs. Leukopak is an enriched leukapheresis product collected from normal peripheral blood. Similarly, in January 2020, Health Canada approved AstraZeneca Canada's Calquence, an oral Bruton’s tyrosine kinase (BTK) inhibitor, to treat adult patients with chronic lymphocytic leukemia (CLL). In October 2020, Haemonetics Corporation announced that it had received US FDA 510(k) clearance for NexSys PCS system with Persona technology.
Thus, such factors are likely to boost the North American leukapheresis market substantially during the forecast period.
To understand geography trends, Download Sample Report
The leukapheresis market is consolidated, competitive, and consists of a few major players. A few major players are currently dominating the market in terms of market share. New product developments, acquisitions, and strategic alliances are some strategies adopted by industry players. Some companies currently dominating the market are Asahi Kasei Medical Co. Ltd, Haemonetics Corporation, Terumo BCT Inc., STEMCELL Technologies Inc., Macopharma, Fresenius SE & Co. KGaA, HemaCare, Key Biologics LLC, AllCells, and StemExpress.
In February 2022, Cryoport Inc. entered a strategic partnership with Cell Matters SA to deliver end-to-end cryopreservation services for leukapheresis-derived therapies supporting both autologous and allogeneic cell therapies to the life sciences industry.
In July 2021, Terumo Blood and Cell Technologies announced a direct offering for physicians to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient's bedside. The company has expanded the functionality of Spectra Optia. The UVA PIT System ECP can now be performed using these devices as a functionally closed, online, multistep system with mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Leukemia
4.2.2 Growing Demand for Leukopaks in Clinical Research Activities
4.3 Market Restraints
4.3.1 High Cost of Therapeutic Leukapheresis
4.3.2 Stringent Regulatory Issues for Donor Recruitment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Leukapheresis Devices
22.214.171.124 Apheresis Devices
126.96.36.199 Leukapheresis Columns and Cell Separators
188.8.131.52 Leukoreduction Filters
5.1.2 Leukapheresis Disposables
5.2 By Application
5.2.1 Therapeutic Applications
5.2.2 Research Applications
5.3 By Geography
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.3.5 South America
220.127.116.11 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Asahi Kasei Medical Co. Ltd
6.1.2 B. Braun Melsungen AG
6.1.3 BioIVT LLC
6.1.4 Fresenius SE & Co. KGaA
6.1.5 Haemonetics Corporation
6.1.6 Kaneka Corporation
6.1.7 Cellero LLC
6.1.9 Medica SPA
6.1.10 Miltenyi Biotec
6.1.11 STEMCELL Technologies Inc.
6.1.13 Sumitomo Bakelite Company Limited (Kawasumi Laboratories Inc.)
6.1.14 Terumo BCT Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Leukapheresis Market market is studied from 2019 - 2027.
What is the growth rate of Global Leukapheresis Market ?
The Global Leukapheresis Market is growing at a CAGR of 7.5% over the next 5 years.
Which region has highest growth rate in Global Leukapheresis Market ?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Leukapheresis Market ?
North America holds highest share in 2021.
Who are the key players in Global Leukapheresis Market ?
Asahi Kasei Medical Co. Ltd, Fresenius SE & Co. KGaA, Haemonetics Corporation, Macopharma, Terumo BCT Inc. are the major companies operating in Global Leukapheresis Market .